Today, Vifor Pharma announced some changes in its management. Dr. Klaus Henning Jensen shall be welcomed by the company in January 2020 as their Chief Medical Officer as well as Member of the Executive Committee. The current Chief Commercial Officer and the member of the Executive Committee, Dario Eklund shall bid farewell to the company by the end of September. A search is underway for a successor.
Dr. Jensen will be joining Vifor Pharma after leaving Sanofi, where he has very recently been serving as the Global Therapeutic Area Head, responsible for cardiovascular as well as metabolism development and diabetes. In this new role of his at Vifor Pharma, he shall be handling Clinical Development, Medical Affairs, and Drug Safety.
Vifor Pharma has also announced the departure of Mr. Dario Eklund. He had joined Vifor Pharma in the year 2014 as their Head of Global Business Operations, prior to becoming the Chief Commercial Officer in the year 2017. He is now planning to pursue opportunities outside of the Vifor Pharma and shall be leaving the organization by September’s end.
The President, Stefan Schulze, of Vifor Pharma Group Executive Committee and the COO, commented that they were very pleased to announce that they had appointed Dr. Klaus Henning Jensen. Doctor Jensen has brought a huge amount of experience by leading global clinical development as well as medical affairs functions at the Sanofi and Novo Nordisk. Schulze said that they were looking forward to welcoming him to their team in January. He said that they would also like to extend their gratitude to Dario Eklund for his amazing leadership and remarkable contributions to their success in the last 5 years.